Insights Archive
Filter by:
July 23, 2024
What Tribal Groups need to know about the Big Three PBMs
Listen to learn why Tribal Nations are especially at risk when working with big PBMs that don’t keep their best interests at heart.
July 15, 2024
ClearScript Solutions: MedEmpower™ Fuel
To help plans manage the rising cost of diabetes and weight management while improving member health, ClearScript offers our MedEmpower Fuel™ program.
July 15, 2024
Drug Spotlight: liraglutide (brand name Victoza)
On June 24, 2024, drug manufacturer Teva Pharmaceuticals announced the launch of an authorized generic formulation of Novo Nordisk’s Victoza (liraglutide). This marks the first generic glucagon-like peptide-1 (GLP-1) agonist available in the U.S. market.
July 15, 2024
ClearScript: Innovating Transparency from the Start
ClearScript was an early pioneer of transparency in pharmacy benefit management. Unlike the Big Three PBMs, we put patients before profits.
June 7, 2024
Biosimilars and your pharmacy benefit plan – Frequently Asked Questions
With the rapid-fire launch of multiple new biosimilars, health plan managers struggle to understand the impact to their pharmacy benefit plan. Listen to get answers from ClearScript’s clinical account team on frequently asked questions about biosimilars.
April 3, 2024
GLP-1s, losing weight or losing money?
GLP-1s are a hot topic in health plans due to their high-price tag and coverage complexity. Following up on ClearScript’s recent GLP-1 webinar, this podcast will answer some new questions and provide additional updates about this drug class.
April 3, 2024
Rezdiffra (resmetirom)
On March 14, 2024, drug manufacturer Madrigal Pharmaceuticals announced the approval of Rezdiffra™, a new, first in class oral therapy for nonalcoholic steatohepatitis (NASH). This disease, which impacts an estimated 6-8 million people in the U.S., is underdiagnosed and if left untreated, it can cause serious liver complications. Read more about this approval and its implications.
April 3, 2024
Understanding Biosimilar Basics
With Humira® biosimilars expected to have a significant impact in 2024, some ClearScript clients are asking for more information. Here we provide the biosimilar basics and what their increasing presence in the marketplace means to the pharmacy benefit.
March 27, 2024
How will the rise of BIOSIMILARS affect your pharmacy benefit plan?
ClearScript’s Clinical Account Executives, Bryan Milbert, PharmD, and Nicole Christian, PharmD, provide a factual presentation on biosimilars’ history, outlook, and how these products could bend your cost curve including perspectives from plan sponsors, members, and prescribers.